Introduction
Retinoids (natural and synthetic) are required for the proper functioning of a large number of cell types with respect to processes such as cell dierentiation and the control of cell growth arrest (Hong and Itri, 1994) . Retinoids can also act as cancer preventive agents and are presently being used successfully to treat some types of cancer . Retinoids either alone or in combination with biological response modi®ers or chemotherapy, have proved to be eective against skin diseases, acute promyelocytic leukemia, cervical cancer, and other malignancies .
Retinoids exert their eects through two families of nuclear receptors. RA receptors (RARs) and retinoid X receptors (RXRs) (Chambon, 1996) , which are liganddependent transcription factors belonging to the superfamily of steroid-thyroid-vitamin D 3 hormone receptors. Three dierent forms of RARs (RARa, -b, and -g) as well as RXRs (RXRa, -b, and -g ) are encoded by distinct genes. Furthermore, each RAR subtype encodes several isoforms which are produced by dierent promoters and/or alternate splicing (Chambon, 1996) . Retinoid receptors activate gene expression by binding to response elements (RAREs and RXREs) present in the promoter regions of RA responsive genes (Chambon, 1996) . The RAR and RXR isotypes are expressed dierently during development and dierentiation Chambon, 1996) , suggesting that each of them may have distinct and speci®c functions. All-trans retinoic acid (RA) speci®cally binds and activates RARs, whereas 9-cis-RA binds and activates both RARs and RXRs. Furthermore, RARb is unique because it is primarily expressed in epithelial cells and exhibits induced expression in response to RA, mediated by an enhancer element found in its promoter, the bRARE (Homan et al., 1990) . Autoregulation of the RARb gene presumably plays a critical role in amplifying the RA response. Although transcripts for three dierent RAR genes are expressed in many mammary carcinoma cell lines, several research groups have recently provided evidence that RARb mediates the growth-inhibitory eects of RA on human breast and ovarian cancer cells (Swisshelm et al., 1994; Seewaldt, 1995; Liu et al., 1996a) .
The actions of cyclic AMP are well known in the regulation of various cellular functions including cell proliferation, dierentiation and gene induction, through the activation of cyclic AMP-dependent protein kinase (PKA) (Krebs and Beavo, 1979) . We and others have recently demonstrated that downregulation of PKA type I by cyclic AMP analogs, and RIa antisense induces apoptosis in several cancer cell lines (Cho-Chung, 1990; Lanotte, 1991; Srivastava et al., 1998a,b) . Furthermore, intracytoplasmic microinjection of puri®ed PKA catalytic subunit commits the cells to death (Vintermyr, 1993) . These results suggest a direct involvement of PKA in the regulation of apoptosis.
In advanced or recurrent malignant diseases, RA is not very eective even at doses that are toxic to the host. Therefore, insight into the molecular mechanisms that regulate apoptosis in tumor cells and identifica-tion of cytotoxic agents that enhance or restore the ability of tumor cells to undergo apoptosis may be crucial for more eective therapies. Thus, the development of new chemotherapeutic agents and new combination regimens are highly desirable. Synergistic eects in growth inhibition of cancer cells in culture have been observed when retinoids are administered in combination with other agents such as antiestrogen (Koga and Sutherland, 1991) or interferon (Widschwendter, 1995) . We have previously demonstrated that retinoic acid (9-cis-RA, 13-cis-RA or all-trans-RA) synergizes with a site selective analog 8-Cl-cAMP in inducing apoptosis and cell cycle arrest in the Ewing's sarcoma CHP-100 cells (Srivastava et al., 1998c) , but the intracellular mechanism(s) of synersism is not known. The purpose of these studies was to examine the intracellular mechanism(s) of synergistic eects of retinoic acid (9-cis-RA, 13-cis-RA or all-trans-RA) and 8-Cl-cAMP on growth arrest and apoptosis in OVCAR-3 and OVCAR-8 ovarian cancer cells.
Results

Synergistic eects of a retinoic acid and 8-Cl-cAMP on cell viability and cell cycle arrest
To evaluate the responsiveness of OVCAR-3 and OVCAR-8 ovarian cancer cells to either RA (9-cis-RA, 13-cis-RA or all-trans-RA) or a cyclic AMP analog 8-Cl-cAMP, we ®rst analysed their eects on growth inhibition. Treatment of OVCAR-3 cells with all-trans-RA resulted in cell growth inhibition in a dose dependent manner (Figure 1a) . Similarly, 8-Cl-cAMP inhibited growth of OVCAR-3 cells in a dosedependent manner (Figure 1b) . Interestingly, 8-ClcAMP acted synergistically with all-trans-RA in inhibiting the growth of OVCAR-3 cells (Figure 1a and b). Synergistic eects between 8-Cl-cAMP and other retinoic acid analogs 9-cis-RA or 13-cis-RA on growth inhibition in OVCAR-3 cells were also noticed (data not shown). By comparison, 8-Cl-cAMP (1 mM) acted synergistically with 9-cis-RA, 13-cis-RA or alltrans RA (1 nM) in inhibiting the growth of OVCAR-8 cells (data not shown). Based on these experiments it is clear that 1 mM dose 8-Cl-cAMP gave maximum growth inhibition when combined with a low dose (1 nM) of retinoic acid. We, therefore, decided to use these doses in future experiments to obtain maximum synergism.
Since combined treatment of RA and 8-Cl-cAMP inhibited cell viability, it was of interest to examine whether this combination caused cell cycle arrest. Low doses of RA (9-cis-RA, 13-cis-RA, all-trans-RA, 1 nM) and 8-Cl-cAMP (1 mM) alone had little eect on Figure 1 Synergistic eects of retinoic acid (9-cis-RA, 13-cis-RA or all-trans-RA) and/or 8-Cl-cAMP on growth inhibition in OVCAR-3 and OVCAR-8 cells. (a) Inhibition of cell growth by varying concentrations of all-trans-RA (0.0001 ± 100 mM) with a single dose of 8-Cl-cAMP (1 mM) in OVCAR-3 cells. Cells were treated with all-trans-RA and/or 8-Cl-cAMP for 5 days. Data (mean+s.e. of quadruplicate determinations) represent one of three separate experiments that gave similar results. (b) Inhibition of cell growth by varying concentrations of 8-Cl-cAMP (0.001 ± 15 mM) with a single dose of all-trans-RA (1 nM) in OVCAR-3 cells. Cells were treated with all-trans-RA and/or 8-Cl-cAMP for 5 days. Data (mean+s.e.m.) represent means of four replicates. Data represent one of three separate experiments that gave similar results growth arrest at G0/G1 stage of the cell cycle (Table  1) . Interestingly, combined treatment of 8-Cl-cAMP (1 mM) and RA (9-cis-RA, 13-cis-RA or all-trans-RA, 1 nM) resulted in synergistic eects on growth arrest at G0/G1 stage of the cell cycle (Table 1) .
Caspase-3 mediates retinoic acid and 8-Cl-cAMPinduced apoptosis
Apoptosis is characterized by cell shrinkage, membrane blebbing, chromatin condensation and nuclear fragmentation (Wyllie, 1995; White, 1996) . We ®rst con®rmed the induction of apoptosis caused by RA and/or 8-Cl-cAMP. As expected, treatment of OV-CAR-3 and OVCAR-8 cells with RA (9-cis-RA, 13-cis-RA or all-trans-RA, 1 nM) plus 8-Cl-cAMP (1 mM) caused an increase in apoptotic nuclei as compared to RA-, 8-Cl-cAMP-treated or untreated control cells (Figure 2a ). DNA fragmentation of OVCAR-3 and OVCAR-8 cells treated with retinoic acid plus 8-ClcAMP was also found by agarose gel electrophoresis (data not shown). In addition to DNA analysis, apoptosis was also assessed by annexin V-FITC staining, leading to similar results (data not shown).
To gain insight into the molecular eector pathway(s) of retinoic acid 8-Cl-cAMP-induced apoptosis, we ®rst analysed whether caspase-3 was involved as downstream eector in death signaling pathway(s) mediating apoptosis in OVCAR-3 and OVCAR-8 cells. While ineective alone, combined treatment of OVCAR-3 cells with a low dose of retinoic acid (9-cis-RA, 13-cis-RA, or all-trans-RA, 1 nM) and 8-Cl-cAMP (1 mM) resulted in activation of caspase-3 by cleaving it to 20 kD subunit (Figure 2b ). We next examined the caspase-3 activity over a period of time to determine if caspase-3 activity was a rate limiting step in the process of programmed cell death (Figure 2c ). There was a slight caspase-3 activity which began after 30 h in OVCAR-3 cells treated with either a low dose of alltrans-RA (1 nM) or 8-Cl-cAMP (1 mM) (Figure 2c ). When cells were treated with all-trans-RA plus 8-ClcAMP, caspase-3 activity began at 30 h and reached a maximum level (®vefold over that of single agent treatment) by 120 h (Figure 2c) .
It has been shown that caspases play signi®cant roles in execution of apoptosis induced by chemotherapeutic drugs, and inactivation of these caspases by caspase inhibitors could block drug-induced apoptosis (Henkart, 1996) . We therefore examined the eects of caspase inhibitors z-VAD-fmk, and z-DEVD-fmk on RA and 8-Cl-cAMP-induced apoptosis in OVCAR-3 and OVCAR-8 cells. Interestingly, caspase inhibitors z-DEVD-fmk, and z-VAD-fmk were eective in blocking all-trans RA plus 8-Cl-cAMP-induced apoptosis in OVCAR-3 cells (Figure 2d ), and OVCAR-8 cells (data not shown). These results con®rmed our ®ndings that retinoic acid plus 8-Cl-cAMP acted in a synergistic fashion to induce apoptosis in ovarian cancer cells through activation of caspase-3.
Cleavage of PARP and DNA-PKcs in retinoic acid and 8-Cl-cAMP treated cells
Recently, poly(ADP ribose)polymerase (PARP) cleavage has been used as an index of apoptosis induced by a variety of anti-cancer drugs (Lazebnik et al., 1994; Henkart, 1996) . Therefore, we measured the cleavage of PARP to con®rm that cells were undergoing apoptosis upon drug treatment. Combined treatment with RA (9-cis-RA, 13-cis-RA or all-trans-RA, 1 nM) plus 8-Cl-cAMP (1 mM) resulted in cleavage of Figure 2 Induction of apoptosis and activation of caspase-3 by combined treatment of retinoic acid plus 8-Cl-cAMP. (a) OVCAR-3 and OVCAR-8 cells treated with retinoic acid (9-cis-RA, 13-cis-RA or all-trans-RA, 1 nM) and 8-Cl-cAMP (1 mM), alone or in combination, for 5 days were examined for apoptosis. Data (mean+s.e. of quadruplicate determinations) represent one of three separate experiments that gave similar results. (b) Caspase-3 cleavage due to combined treatment of RA plus 8-Cl-cAMP was measured by the Western blot analysis. Cells were treated with retinoic acid (9-cis-RA, 13-cis-RA or all-trans-RA, 1 nM), alone or in combination, for 5 days. (c) Caspase-3 activation by combined treatment of RA plus 8-Cl-cAMP over time. OVCAR-3 cells treated with all-trans-RA (1 nM) and 8-Cl-cAMP (1 mM), alone or in combination, for various time points as shown in the graph. (d) Caspase inhibitors z-VAD-fmk, and z-DEVD-fmk block apoptosis induced by all-trans-RA plus 8-Cl-cAMP in OVCAR-3 cells. Cells were treated with all-trans RA (1 mM) and 8-Cl-cAMP (1 mM), alone or in combination, for 5 days. Data represent one of three separate experiments that gave similar results p116PARP to its 85-kD fragment in OVCAR-3 cells ( Figure 3a ). By comparison, cleavage of PARP was not observed with low doses of 8-Cl-cAMP, RA or in untreated control cells (Figure 3a) . Similarly, retinoic acid and 8-Cl-cAMP acted synergistically in activating caspase-3 and cleaving PARP in OVCAR-8 cells (data not shown).
To determine whether DNA-PKcs (catalytic subunit) might be a target for proteolytic degradation during DNA damage-induced apoptosis (Gottlieb and Jackson, 1993) , we used immunoblotting with antibody targeted against catalytic subunit, with extracts from OVCAR-3 cells treated with RA and/or 8-Cl-cAMP. The treatment of OVCAR-3 cells with either a low dose of RA (9-cis-RA, 13-cis-RA or all-trans-RA, 1 nM) or 8-Cl-cAMP (1 mM), followed by immunoblotting, had no eect on DNA-PKcs degradation ( Figure  3b ). However, combined treatment of OVCAR-3 cells with RA plus 8-Cl-cAMP resulted in DNA-PKcs degradation to 240 kD fragment (Figure 3b ). Similarly, combined treatment of OVCAR-8 cells with RA plus 8-Cl-cAMP resulted in degradation of DNA-PKcs (data not shown).
Since DNA-PKcs must associate with Ku, the DNAtargeting component of the complex, to be activated (Gottlieb and Jackson, 1993) , we also determined the fate of Ku70 and Ku86 in OVCAR-3 and OVCAR-8 cells during apoptosis. There was no evidence for the degradation of either protein in OVCAR-3 (Figure 3c ) and OVCAR-8 cells (data not shown) exposed to retinoic acid and/or 8-Cl-cAMP.
To determine whether the cleavage of DNA-PKcs interferes with its function, we measured the activity of DNA-PK in OVCAR-3 and OVCAR-8 cells treated with all-trans-RA and 8-Cl-cAMP using a peptide substrate . It is evident from the results in Figure 3d that kinase activity is reduced to less than 25% upon treating cells with a combination of all-trans-RA plus 8-Cl-cAMP in both OVCAR-3 and OVCAR-8 cells. The loss of DNA-PK activity therefore correlates with the degradation of DNA-PKcs.
Redistribution of cytochrome c in retinoic acid and 8-Cl-cAMP treated cells
Mitochondrial dysfunction has been observed in the early stages of apoptosis (Bernardi et al., 1994) . Both mitochondrial depolarization and the loss of cytochrome c from the mitochondrial intermembrane space to the cytosol have been proposed as early central events in apoptotic cell death (Liu et al., 1996b; Reed, 1997) . Recently, cytochrome c release has been shown to activate caspase-3, thus continuing transmission of the apoptotic program (Liu et al., 1996b) . We next determined the presence of cytochrome c in the cytosolic and mitochondrial fractions of cells treated with all-trans-RA and/or 8-Cl-cAMP (Figure 4a ). Treatment of OVCAR-3 cells with either a low dose of all-trans-RA (1 nM) or 8-Cl-cAMP (1 mM) had no eect on cytochrome c release from the mitochondria to the cytosol (Figure 4a ). Combined treatment of all-trans-RA plus 8-Cl-cAMP caused a redistribution of cytochrome c from the mitochondria to the cytosol in OVCAR-3 cells (Figure 4a) . Similarly, cytochrome c release from the mitochondria to the cytosol was observed in OVCAR-8 cells due to combined treatment of all-trans-RA plus 8-ClcAMP. In contrast to the cytochrome c release, the inner mitochondrial membrane protein cytochrome oxidase remained in the mitochondrial fraction in OVCAR-3 cells (Figure 4a ).
Mitochondrial permeability transition (MPT) refers to the regulated opening of a large, nonspeci®c pore in the inner mitochondrial membrane (Bernardi et al., 1994) . The MPT causes the loss of the mitochondrial Lack of degradation of Ku70 and Ku86, the DNA-binding components of DNA-PK, after the treatment of cells with RA (9-cis-RA, 13-cis-RA and all-trans-RA, 1 mM) and/or 8-Cl-cAMP (1 mM) in OVCAR-3 cells. DNA-PKcs, Ku70 and Ku86 were measured by Western blot analysis. (d) DNA-PK activity in alltrans-RA and/or 8-Cl-cAMP treated OVCAR-3 and OVCAR-8 cells undergoing apoptosis. For DNA-PK activity, extracts were prepared and assayed with a synthetic peptide (EPPLSQEA-FADLWKK). Cells were treated with all-trans-RA (1 nM) and/or 8-Cl-cAMP (1 mM) for 5 days. Data (mean+s.e. of quadruplicate determinations) represent one of three separate experiments that gave similar results membrane potential (DC m ) (Nieminen et al., 1995) . Thē uorescent dye DiOC 6 (3) localizes to mitochondria, and the MPT reduces the accumulation of DiOC 6 (3) as a consequence of the loss of DC m (VavssiaÈ re et al., 1994) . Treatment of OVCAR-3 cells with all-trans-RA plus 8-Cl-cAMP produced a steady decline in DC m (Figure 4b ), which began after 10 h. By comparison, treatment of OVCAR-3 cells with either all-trans-RA or 8-Cl-cAMP had slight eects after 60 h (Figure 4b ). These data suggest that loss of mitochondrial membrane potential (Figure 4b ) precedes caspase-3 activation (Figure 2c) , and the caspases act downstream of mitochondrial apoptotic events.
Induction of RARb by combined treatment of retinoic acid and 8-Cl-cAMP
To determine which RAR subtype is involved in RAinduced growth inhibition, we investigated the expression of RAR (a, b and g) and RXR (a, b and g) in OVCAR-3 and OVCAR-8 cells. Both cell types expressed RARa, RARg, RXRa, RXRb and RXRg, but not RARb under the conditions used (Figure 5a ). Since combined treatment with a low dose of all-trans-RA plus 8-Cl-cAMP inhibited cell viability and induced apoptosis in a synergistic fashion, it was of interest to examine if this synergistic eect was due to increased expression of RARb gene because its promoter contains a functionally active CRE-related motif (Kruyt, 1992) . Treatment of OVCAR-3 and OVCAR-8 cells with 1 mM all-trans-RA resulted in induction of RARb mRNA (data not shown). In order to achieve maximum synergism between RA and 8-ClcAMP, we used a low dose (1 nM) of all-trans-RA along with a low dose of 8-Cl-cAMP (1 mM). When a low dose of all-trans-RA (1 nM) was used, the induction of RARb mRNA was not observed in OVCAR-3 and OVCAR-8 cells (Figure 5b and c) . By comparison, a low dose of 8-Cl-cAMP (1 mM) induced a slight RARb mRNA. Interestingly, combined treatment of these low doses of 8-Cl-cAMP and alltrans-RA had a synergistic eect on the induction of RARb mRNA in both cell types (Figure 5b and c) . These data suggest that induction of RARb may be responsible for the synergistic eects of all-trans-RA and 8-Cl-cAMP.
A cyclic AMP response element-related sequence in the 7180/763 fragment enhances RARb2 activation
The presence of a putative cis-acting element, cyclic AMP response element (CRE)-related sequence at position 799 to 792 in human RARb2 promoter has been reported (Kruyt, 1992) . This sequence TGATGTCA diers from the eight-base consensus CRE sequence, TGACGTCA (Kruyt, 1992) , by one base substitution (C?T) at position four. In addition, this element is functionally active as a CRE since it can bind members of the CREB/ATF transcription factor family and mediates the stimulatory eect of cyclic AMP on RA-dependent RARb2 promoter activation in human fetal kidney 293 cells (Kruyt, 1992 ). Since we observed synergistic eects between 8-Cl-cAMP and retinoic acid on RARb activation, it was of interest to determine the functional contribution of CRE in RARb2 activation. In order to answer this question, 7180/+156 CAT reporter construct was generated in which the CRE motif was disrupted by site-directed mutagenesis (Figure 6a) , and the responses of RA and/ or cyclic AMP were determined in OVCAR-3 and OVCAR-8 cells transfected with bRARE-tk-CAT construct ( Figure 6b ). As can be seen in Figure 6b , treatment of cells with 8-Cl-cAMP or forskolin resulted in induction of CAT activity. Interestingly, 8-Cl-cAMP or forskolin acted synergistically with all-trans-RA in trans-activating RARb2 (Figure 6b ). Furthermore, mutation of the CRE abolished eects of 8-ClcAMP/forskolin alone and the synergistic eects of 8-Cl-cAMP/forskolin plus all-trans-RA on RARb2 transactivation (Figure 6b ). These results demonstrate that the CRE is responsible for the enhancement of RAdependent RARb2 promoter activation that we observed on the 7180/+156 promoter region.
Discussion
In the present study, we have demonstrated that the apoptosis and growth arrest in human ovarian cancer cells can be synergistically regulated by the combined treatment of retinoic acid and a site selective cyclic AMP analog 8-Cl-cAMP. The combination of RA and 8-Cl-cAMP resulted in synergistic induction of the RARb gene that was correlated with inhibition in cell growth, apoptosis and cell cycle arrest at G0/G1. In addition, induction of apoptosis by RA plus 8-ClcAMP resulted in the release of cytochrome c from the mitochondria, loss in the mitochondrial membrane potential, activation of caspase-3, and cleavage of PARP and DNA-PKcs. This is the ®rst report showing that the retinoic acid and 8-Cl-cAMP acted synergistically in suppressing ovarian cancer cell growth and inducing apoptosis through regulation of RARb gene and activation of caspase-3.
Many of the eects of retinoids result from modulation of gene expression. Nuclear retinoid receptors, ligand-activated transcription enhancing factors, play a major role in mediating the eects of retinoids on gene expression and consequently on the growth and dierentiation of both normal and tumor cells Hong et al., 1995; Liu et al., 1996a) . Changes in the expression of speci®c receptors could abrogate the retinoid signaling pathway and result in enhanced carcinogenesis. Recently, several studies have reported the loss of RARb expression in a The fragments in (a) were fused to the CAT gene, and RA and cyclic AMP-dependent activation was determined by transient transfection using CAT assay. Cells were plated on 60-mm dishes and transfected with a total of 2 mg/ml DNA along with lipofectamine. After 1 day, culture medium was replaced, and the cells were treated with or without drugs for 36 h. At the end of incubation, cells were harvested and washed twice with PBS, and cellular lysates were prepared. Data (mean+s.e. of quadruplicate determinations) represent one of three separate experiments that gave similar results number of malignant tumors, including lung carcinoma, squamous cell carcinoma of the head and neck, and breast carcinoma (Swisshelm et al., 1994; Houle et al., 1993; Zhang et al., 1994; Xu et al., 1997a) . In vitro experiments have demonstrated that RARb mediates retinoid action in breast cancer cells by promoting apoptosis (Liu et al., 1996a; Xu et al., 1997b) . Based on in vitro and in vivo experiments, RARb has been implicated as a tumor suppressor (Houle et al., 1993; Berard et al., 1996; Xu et al., 1997b) . Interestingly, transfection of a human epidermoid lung cancer in vitro with an RARb expression vector resulted in decreased tumorigenicity (Houle et al., 1993) . In addition, transgenic mice expressing antisense RARb2 developed carcinomas 14 ± 18 months after birth (Berard et al., 1996) . Moreover, when the patients were treated with oral retinoids, RARb expression increased in premalignant head and neck cancer lesions and these lesions regressed . In the present study, all-trans RA acted synergistically with 8-Cl-cAMP in inducing apoptosis and enhancing the expression of RARb by trans-activating bRARE possibly because RARb2 promoter contains a functional cyclic AMP-response element (CRE)-related motif (TGATGTCA) (Kruyt et al., 1992) . Together, these data clearly demonstrate that RARb can mediate the all-trans-RA-induced growth inhibition and apoptosis in ovarian cancer cells. Thus, activation of the RARb pathway may be critical for growth inhibition and induction of apoptosis.
It has been reported that a CRE-related element in the RARb2 promoter contributes to the transactivation of the promoter by RA (Kruyt et al., 1992) , which is known to be mediated by a RAresponse element located in the proximity of the TATA-box (de . This CRE-like element is located at position 799 to 792 in the human RARb2 promoter and consists of the b motif TGATGTCA, which diers in only one base (underline) from the consensus CRE, TGACGTCA. In transient transfection experiments, Kruyt et al. (1992) demonstrated that forskolin was able to enhance RAdependent RARb2 promoter activation via CRErelated element in human fetal kidney 293 cells, a ®nding that shows that this element can mediate transactivation upon activation of the cyclic AMP signal transduction pathway. In the present study, 8-Cl-cAMP or forskolin acted synergistically with alltrans-RA in activating RARb, and these synergistic eects were diminished when mutated CRE (nonfunctional) was used in RARb2 promoter-tk-CAT construct (Figure 6 ), suggesting that these synergistic eects on RARb gene expression were due to the CRErelated motif present in RARb promoter.
Apoptosis, a type of cellular suicide, is a physiological event important for host defense, development, homeostasis, and aging (Wyllie, 1995; White, 1996) . The family of cysteinyl aspartate-speci®c proteinases (caspases) mediates a highly speci®c proteolytic cleavage early in the process of apoptosis (Lazebnik et al., 1994; Henkart, 1996) . Mitochondrial dysfunction, such as loss of mitochondrial transmembrane potential, has also been observed in the early stages of apoptosis (Reed, 1997) . Recently, cytochrome c release from the mitochondria to the cytosol has been shown to activate caspase-3, thus continuing transmission of the apoptotic program (Liu et al.,1996b) . In the present study, combined treatment with all-trans-RA plus 8-ClcAMP resulted in the release of cytochrome c from the mitochondria to the cytosol, loss in mitochondrial membrane potential and activation of caspase-3. All these events have been shown to be important for induction of apoptosis.
Several proteins which are cleaved during apoptosis have been shown to be speci®c targets for caspase-3 including DNA-dependent protein kinase (DNA-PK) (Song et al., 1996) , and poly(ADP-ribose)polymerase (PARP) (Kaufmann et al., 1993) . DNA-PK is composed of a 460-kD catalytic subunit tentatively termed DNA-PKcs (Hartley et al., 1995) and a DNAbinding component Ku protein (p70/p86) (Gottlieb and Jackson, 1993) . It has been revealed that DNA-PK is involved at least in DNA double strand break repair. Another enzyme implicated in DNA repair, PARP, is cleaved and inactivated during apoptosis, suggesting that some DNA repair proteins may be selectively targeted for destruction during apoptosis. In the present study, we have demonstrated that DNAPKcs, the catalytic subunit of DNA-PK, and PARP are preferentially degraded due to combined treatment with retinoic acid plus 8-Cl-cAMP in ovarian cancer cells.
The synergistic growth inhibitory eects of 8-ClcAMP and retinoic acids demonstrated in this study are important. The growth inhibition was achieved at pharmacologically achievable concentrations for 8-ClcAMP (1 mM) and retinoic acid (1 nM). In a phase I clinical study of 8-Cl-cAMP, plasma concentrations of 8-Cl-cAMP as high as 4 mM were nontoxic (Tortora et al., 1995) , and the synthetic retinoid, N-(4-hydroxylphenyl) retinamide (4HPR) produces growth inhibition at pharmacologically achievable concentrations of 1 ± 2 mM (Sabichi et al., 1998) . This suggests feasibility of a combination treatment with 8-Cl-cAMP and a retinoic acid analog such as all-trans-RA.
Because RARb expression is absent or decreased in human cancer cell lines and primary tumors, induction of apoptosis through induction and transactivation of RARb expression by combination chemotherapy is a possible approach for cancer treatment. Induction of RARb expression by retinoic acid plus 8-Cl-cAMP was associated with the activation of caspase-3 and induction of apoptosis. Thus, combined treatment with retinoic acid and 8-Cl-cAMP may have therapeutic potential for malignancies in humans.
Materials and methods
Reagent
Retinoic acids (9-cis-RA, 13-cis-RA and all-trans-RA) and forskolin were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Retinoic acids were dissolved in ethanol to a concentration of 1 M, stored at 7208C and protected from light. Anit-poly(ADP-ribose)polymerase (PARP), anti-Ku-70, anti-Ku-86, and anti-DNA-PKcs antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Enhanced chemiluminescence Western blot detection kit was purchased from Amersham Life Sciences Inc. (Arlington Heights, IL, USA). DiOC 6 (3) and anti-cytochrome oxidase (subunit IV) antibody were purchased from Molecular Probes (Eugene, OR, USA). Anti-cytochrome c antibody was purchased from Pharmin-gen (San Diego, CA, USA). The 8-Cl-cAMP was synthesized at Drug Synthesis and Chemistry Branch, National Cancer Institute (Bethesda, MD, USA). The protein concentration was determined with the BCA reagent, Pierce (Rockford, IL, USA).
32 P-adenosine-5'-triphosphate (speci®c activity 7000 Ci/mmol) was purchased from ICN Pharmaceuticals, Inc. (Irvine, CA, USA). The caspase-3 assay kit was purchased from Clontech Laboratories, Inc. (Palo Alto, CA, USA).
Cell growth assay
The human ovarian cancer (NIH: OVCAR-3 and OVCAR-8) cells were obtained from Dr Kurt Stromberg (FDA, Bethesda, MD, USA). Cells (1610 3 /well) were plated in a 24-well plate containing RPMI 1640 supplemented with 10% fetal calf serum (FCS) and 1% antibiotics at 378C with 5% CO 2 . Retinoic acid (9-cis-RA, 13-cis-RA or alltrans-RA) or 8-Cl-cAMP was added (8 h after seeding) to four replicate wells. After 5 days, cells were harvested and counted in a coulter counter. These studies were carried out in the presence of FCS which is expected to have retinoic acids.
Apoptosis
To assay nuclear morphology (apoptotic nuclei), cells were washed with PBS, ®xed with 70% ethanol for 1 h, and stained with 1 mM Hoechst 33258 (Sigma) for 30 min. The nuclear morphology of cells were visualized by ā uorescence microscope (Olympus BH2). Fluorescent nuclei were screened for normal morphology (unaltered chromatin), and apoptotic nuclei comprising those with fragmented (scattered) and condensed chromatin were counted. Apoptosis was expressed as the percentage of apoptotic nuclei/10 3 nuclei.
Plasmid construction for CAT assay
Site-directed mutant of the RARb2 promoter was constructed by using the Altered Sites in vitro Mutagenesis system kit (Promega, Madison, WI, USA). The structure of the mutant is shown in Figure 6a . For mutagenesis, ssDNA derived from the vector pSELECT inserted into the HpaIIBamHI (7180/+156) promoter fragment functioned as a template. The DCRE construct was made by using the synthetic oligonucleotide, 5'-ATCCTGGGAGTTGGaGATGTtAGACTAGTTGGGTC-3', with the altered bases shown in lower case letters, abolishing the proper function of this element (Angel, 1987; Foulkes, 1991) . After con®rming the sequence of the mutant constructs by ds DNA sequencing, using the T7 sequencing kit (Pharmacia Biotech Inc., Piscataway, NJ, USA), the HpaII-BamHI fragments were ligated in ptk-CAT.
Northern blot analysis
For Northern blot analysis, total RNAs were prepared by using RNAzole (GIBCO BRL, Grand Island, NY, USA). About 30 mg of total RNA was fractionated on a 1% agarose gel, transferred to nylon ®lters, and probed with the 32 P-labeled ligand-binding domain of RAR (a, b or g) or RXR (a, b or g) cyclic DNA. To determine that equal amounts of RNA were used, the ®lters were also probed with b-actin cyclic DNA.
Transient transfection and CAT assay
To measure the transcriptional activation of bRARE in ovarian cancer cells, bRARE (7180/+156 or DCRE) linked with the chloramphenicol acetyltransferase (CAT) gene (bRARE-tk-CAT) was used as a reporter gene ( Figure  6a ). bRARE-tk-CAT (2.0 mg) and 3.0 mg of b-galactosidase expression vector (pCH 110, Pharmacia) were transiently transfected into cells along with lipofectamine (GIBCO, BRL). Cells were grown in the presence or absence of alltrans-RA, 8-Cl-cAMP or forskolin. Transfection eciency was normalized by b-galactosidase activity.
Measurement of mitochondrial energization
Mitochondrial energization was determined as the retention of the dye 3,3'-dihexyloxacarbocyanine (DiOC 6 )(3). Cells (5610 5 in 500 ml of complete RPMI 1640 medium) were loaded with 100 nM DiOC 6 (3) during the last 30 min of treatment. The cells were then pelleted at 700 g for 10 min. The supernatant was removed, and the pellet was resuspended and washed in PBS two times. The pellet was then lysed by the addition of 600 ml of deionized water followed by homogenization. The concentration of retained DiOC 6 (3) was determined on a¯uorescence spectrometer (Cyto Fluor PerSeptive Biosystems, Framingham, MA, USA) at 480 nm excitation and 510 nm emission (Pastorino et al., 1998) .
Subcellular fractionation
Mitochondria and cytosolic (S100) fractions were prepared by resuspending cells in 0.8 ml ice-cold buer A (250 mM sucrose, 20 mM HEPES, 10 mM Kcl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 17 mg/ml phenylmethylsulfonyl¯uoride, 8 mg/ml aprotinin, 2 mg/ml leupeptin [pH 7.4]) (Heiden et al., 1997) . Cells were passed through an ice-cold cylinder cell homogenizer. Nuclei were pelleted by a 10 min, 750 g spin. The supernatant was spun at 10 000 g for 25 min. This pellet was resuspended in buer A and represents the mitochondrial fraction. The supernatant was spun at 100 000 g for 1 h. The supernatant from this ®nal centrifugation represents the S100 fraction.
Western blot analysis
Cells (1610 6 ) were plated in 10-cm dishes and incubated with drugs as described in Figure legends . Cells were washed twice with PBS, scraped, centrifuged, and the cell pellets were lysed in lysis buer (0.1 M NaCl, 5 mM MgCl 2 , 1% Nonidet P-40, 0.5% sodium deoxycholate, 20 mM TrisHCl, pH 7.4 containing proteolysis inhibitors, vortexed, passed through a 22-gauge needle twice, allowed to stand for 30 min at 48C, and centrifuged at 750 g for 20 min; the resulting supernatants were used as cell lysates. Lysates were electrophoresed on 6 ± 20% SDS ± PAGE, blotted onto nitrocellulose membrane, probed with antibody and visualized by the enhanced chemiluminescence kit.
DNA-PK activity assay
DNA-PK assays were performed according to manufacturer's instructions (Promega, Madison, WI, USA). In brief, assays were performed in a ®nal volume of 20 ml containing 25 mM HEPES-KOH, pH 7.5, 4 mM MgCl 2 , 13 mM spermidine, 1 mM DTT, 5% glycerol 0.1% NP-40, 2 mM ATP, 50 mM KCl and [ 32 P]ATP (3000 Ci/mmol, 0.5 ml). The substrate for DNA-PK phosphorylation was a synthetic peptide (EPPLSQEAFADLWKK), and was present in reactions at a concentration of 500 mM. Each sample was also assayed and was present in reactions at a concentration of 500 mM. Each sample was also assayed in the presence of non-substrate peptide EPPLSEQ-FADLWKK. Reaction mixture was incubated for 10 min at 308C, and the reaction was stopped by adding 20 ml of 30% acetic acid. Ten microliter of the reaction products was spotted onto a 262 cm piece of Whatman P-81 phosphocellulose paper. Filters were air-dried, washed four times with 15% acetic acid and counted in a scintillation counter.
Cell cycle analysis
OVCAR-3 and OVCAR-8 cells were treated with drugs, cultured for 5 days and harvested for cell cycle analyses. In brief, 1610 6 cells were washed in ice-cold PBS and pelleted in a 12675 mm culture tube. The pellets were resuspended in 0.875 ml ice-cold PBS and 0.125 ml of ice-cold 2% paraformaldehyde solution was added. The tubes containing the cells were incubated at 48C for 1 h, centrifuged for 5 min at 250 g, and supernatant was discarded. After ®xation, cells were permeabilized by adding 1 ml of 0.2% Tween 20 in PBS at room temperature and incubated for 15 min at 378C. Cells were washed by adding an additional 1 ml of PBS and centrifuged. After aspiration of supernatant, cells were resuspended in 1 ml PBS containing DAPI (4',6-diamidino-2-phenylindole) at a ®nal concentration of 1 mg/ml for 30 min. The samples were read on a FACStar + Flow Cytometer (Becton Dickinson Immunocytometry Systems, Mountain View, CA, USA) using Lysys II software program.
Abbreviations
RARb, retinoic acid receptor b; RA, retinoic acid, PKA, cAMP-dependent protein kinase; C, catalytic subunit; PARP, Poly(ADP-ribose)polymerase PARP; DNA-PK, DNA-dependent protein kinase.
